Drug Profile

Research programme: autoimmune disease therapies - Resolve Therapeutics

Alternative Names: RSLV-125

Latest Information Update: 20 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Washington University
Developer Resolve Therapeutics
Class Anti-inflammatories; Biological proteins; Recombinant fusion proteins; Vascular disorder therapies
Mechanism of Action Interferon alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

19 Jul 2023 Preclinical trials in Vasculitis in USA (Parenteral) (before July 2023) (Resolve Therapeutics Pipeline, July 2023)
04 Nov 2017 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in USA (Parenteral)
17 Mar 2014 RSVL 132 has entered clinical development for for Systemic lupus erythematosus in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com